Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue 1.4 Market Analysis by Type 1.4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 CT-2009 1.4.3 POL-6014 1.4.4 ARO-AAT 1.4.5 ALNAAT-02 1.4.6 Others 1.5 Market by Application 1.5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026 1.5.2 Clinic 1.5.3 Hospital 1.5.4 Others 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Alpha- Antitrypsin Deficiency Treatment Market Perspective (2015-2026) 2.2 Alpha- Antitrypsin Deficiency Treatment Growth Trends by Regions 2.2.1 Alpha- Antitrypsin Deficiency Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Alpha- Antitrypsin Deficiency Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Alpha- Antitrypsin Deficiency Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Alpha- Antitrypsin Deficiency Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Market Size 3.1.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Revenue (2015-2020) 3.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio 3.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Alpha- Antitrypsin Deficiency Treatment Revenue in 2019 3.3 Alpha- Antitrypsin Deficiency Treatment Key Players Head office and Area Served 3.4 Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service 3.5 Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Type (2015-2020) 4.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2021-2026) 5 Alpha- Antitrypsin Deficiency Treatment Breakdown Data by Application (2015-2026) 5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) 5.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020) 6.2 Alpha- Antitrypsin Deficiency Treatment Key Players in North America (2019-2020) 6.3 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) 6.4 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) 7 Europe 7.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020) 7.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Europe (2019-2020) 7.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) 7.4 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) 8 China 8.1 China Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020) 8.2 Alpha- Antitrypsin Deficiency Treatment Key Players in China (2019-2020) 8.3 China Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) 8.4 China Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) 9 Japan 9.1 Japan Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020) 9.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Japan (2019-2020) 9.3 Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) 9.4 Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020) 10.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) 10.4 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) 11 India 11.1 India Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020) 11.2 Alpha- Antitrypsin Deficiency Treatment Key Players in India (2019-2020) 11.3 India Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) 11.4 India Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020) 12.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Central & South America (2019-2020) 12.3 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) 12.4 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Adverum Biotechnologies, Inc. 13.1.1 Adverum Biotechnologies, Inc. Company Details 13.1.2 Adverum Biotechnologies, Inc. Business Overview and Its Total Revenue 13.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 13.1.4 Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)) 13.1.5 Adverum Biotechnologies, Inc. Recent Development 13.2 Alnylam Pharmaceuticals, Inc. 13.2.1 Alnylam Pharmaceuticals, Inc. Company Details 13.2.2 Alnylam Pharmaceuticals, Inc. Business Overview and Its Total Revenue 13.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 13.2.4 Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 13.2.5 Alnylam Pharmaceuticals, Inc. Recent Development 13.3 Applied Genetic Technologies Corporation 13.3.1 Applied Genetic Technologies Corporation Company Details 13.3.2 Applied Genetic Technologies Corporation Business Overview and Its Total Revenue 13.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Introduction 13.3.4 Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 13.3.5 Applied Genetic Technologies Corporation Recent Development 13.4 Arrowhead Pharmaceuticals, Inc. 13.4.1 Arrowhead Pharmaceuticals, Inc. Company Details 13.4.2 Arrowhead Pharmaceuticals, Inc. Business Overview and Its Total Revenue 13.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 13.4.4 Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 13.4.5 Arrowhead Pharmaceuticals, Inc. Recent Development 13.5 Carolus Therapeutics, Inc. 13.5.1 Carolus Therapeutics, Inc. Company Details 13.5.2 Carolus Therapeutics, Inc. Business Overview and Its Total Revenue 13.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 13.5.4 Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 13.5.5 Carolus Therapeutics, Inc. Recent Development 13.6 Cevec Pharmaceuticals GmbH 13.6.1 Cevec Pharmaceuticals GmbH Company Details 13.6.2 Cevec Pharmaceuticals GmbH Business Overview and Its Total Revenue 13.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Introduction 13.6.4 Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 13.6.5 Cevec Pharmaceuticals GmbH Recent Development 13.7 Dicerna Pharmaceuticals, Inc. 13.7.1 Dicerna Pharmaceuticals, Inc. Company Details 13.7.2 Dicerna Pharmaceuticals, Inc. Business Overview and Its Total Revenue 13.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 13.7.4 Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 13.7.5 Dicerna Pharmaceuticals, Inc. Recent Development 13.8 Digna Biotech, S.L. 13.8.1 Digna Biotech, S.L. Company Details 13.8.2 Digna Biotech, S.L. Business Overview and Its Total Revenue 13.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Introduction 13.8.4 Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 13.8.5 Digna Biotech, S.L. Recent Development 13.9 Editas Medicine, Inc. 13.9.1 Editas Medicine, Inc. Company Details 13.9.2 Editas Medicine, Inc. Business Overview and Its Total Revenue 13.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 13.9.4 Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 13.9.5 Editas Medicine, Inc. Recent Development 13.10 Grifols, S.A. 13.10.1 Grifols, S.A. Company Details 13.10.2 Grifols, S.A. Business Overview and Its Total Revenue 13.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Introduction 13.10.4 Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 13.10.5 Grifols, S.A. Recent Development 13.11 Inhibrx 10.11.1 Inhibrx Company Details 10.11.2 Inhibrx Business Overview and Its Total Revenue 10.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Introduction 10.11.4 Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 10.11.5 Inhibrx Recent Development 13.12 Intellia Therapeutics, Inc. 10.12.1 Intellia Therapeutics, Inc. Company Details 10.12.2 Intellia Therapeutics, Inc. Business Overview and Its Total Revenue 10.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 10.12.4 Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 10.12.5 Intellia Therapeutics, Inc. Recent Development 13.13 International Stem Cell Corporation 10.13.1 International Stem Cell Corporation Company Details 10.13.2 International Stem Cell Corporation Business Overview and Its Total Revenue 10.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Introduction 10.13.4 International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 10.13.5 International Stem Cell Corporation Recent Development 13.14 Ionis Pharmaceuticals, Inc. 10.14.1 Ionis Pharmaceuticals, Inc. Company Details 10.14.2 Ionis Pharmaceuticals, Inc. Business Overview and Its Total Revenue 10.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 10.14.4 Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 10.14.5 Ionis Pharmaceuticals, Inc. Recent Development 13.15 Kamada Ltd. 10.15.1 Kamada Ltd. Company Details 10.15.2 Kamada Ltd. Business Overview and Its Total Revenue 10.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction 10.15.4 Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 10.15.5 Kamada Ltd. Recent Development 13.16 Polyphor Ltd. 10.16.1 Polyphor Ltd. Company Details 10.16.2 Polyphor Ltd. Business Overview and Its Total Revenue 10.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction 10.16.4 Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 10.16.5 Polyphor Ltd. Recent Development 13.17 ProMetic Life Sciences Inc. 10.17.1 ProMetic Life Sciences Inc. Company Details 10.17.2 ProMetic Life Sciences Inc. Business Overview and Its Total Revenue 10.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 10.17.4 ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 10.17.5 ProMetic Life Sciences Inc. Recent Development 13.18 rEVO Biologics, Inc. 10.18.1 rEVO Biologics, Inc. Company Details 10.18.2 rEVO Biologics, Inc. Business Overview and Its Total Revenue 10.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 10.18.4 rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 10.18.5 rEVO Biologics, Inc. Recent Development 13.19 Sangamo BioSciences, Inc. 10.19.1 Sangamo BioSciences, Inc. Company Details 10.19.2 Sangamo BioSciences, Inc. Business Overview and Its Total Revenue 10.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction 10.19.4 Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) 10.19.5 Sangamo BioSciences, Inc. Recent Development 14 Analyst's Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Alpha- Antitrypsin Deficiency Treatment Key Market Segments Table 2. Key Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue Table 3. Ranking of Global Top Alpha- Antitrypsin Deficiency Treatment Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of CT-2009 Table 6. Key Players of POL-6014 Table 7. Key Players of ARO-AAT Table 8. Key Players of ALNAAT-02 Table 9. Key Players of Others Table 10. Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 11. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Regions (US$ Million): 2020 VS 2026 Table 12. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Regions (2015-2020) (US$ Million) Table 13. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2015-2020) Table 14. Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 15. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2021-2026) Table 16. Market Top Trends Table 17. Key Drivers: Impact Analysis Table 18. Key Challenges Table 19. Alpha- Antitrypsin Deficiency Treatment Market Growth Strategy Table 20. Main Points Interviewed from Key Alpha- Antitrypsin Deficiency Treatment Players Table 21. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Players (2015-2020) (Million US$) Table 22. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Players (2015-2020) Table 23. Global Top Alpha- Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2019) Table 24. Global Alpha- Antitrypsin Deficiency Treatment by Players Market Concentration Ratio (CR5 and HHI) Table 25. Key Players Headquarters and Area Served Table 26. Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service Table 27. Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market Table 28. Mergers & Acquisitions, Expansion Plans Table 29. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$) Table 30. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Type (2015-2020) Table 31. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Application (2015-2020) Table 33. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$) Table 34. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2026) Table 35. North America Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$) Table 36. North America Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020) Table 37. North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$) Table 38. North America Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020) Table 39. North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$) Table 40. North America Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020) Table 41. Europe Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$) Table 42. Europe Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020) Table 43. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$) Table 44. Europe Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020) Table 45. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$) Table 46. Europe Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020) Table 47. China Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$) Table 48. China Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020) Table 49. China Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$) Table 50. China Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020) Table 51. China Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$) Table 52. China Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020) Table 53. Japan Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$) Table 54. Japan Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020) Table 55. Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$) Table 56. Japan Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020) Table 57. Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$) Table 58. Japan Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020) Table 59. Southeast Asia Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$) Table 60. Southeast Asia Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020) Table 61. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$) Table 62. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020) Table 63. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$) Table 64. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020) Table 65. India Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$) Table 66. India Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020) Table 67. India Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$) Table 68. India Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020) Table 69. India Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$) Table 70. India Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020) Table 71. Central & South America Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$) Table 72. Central & South America Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020) Table 73. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$) Table 74. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020) Table 75. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$) Table 76. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020) Table 77. Adverum Biotechnologies, Inc. Company Details Table 78. Adverum Biotechnologies, Inc. Business Overview Table 79. Adverum Biotechnologies, Inc. Product Table 80. Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 81. Adverum Biotechnologies, Inc. Recent Development Table 82. Alnylam Pharmaceuticals, Inc. Company Details Table 83. Alnylam Pharmaceuticals, Inc. Business Overview Table 84. Alnylam Pharmaceuticals, Inc. Product Table 85. Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 86. Alnylam Pharmaceuticals, Inc. Recent Development Table 87. Applied Genetic Technologies Corporation Company Details Table 88. Applied Genetic Technologies Corporation Business Overview Table 89. Applied Genetic Technologies Corporation Product Table 90. Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 91. Applied Genetic Technologies Corporation Recent Development Table 92. Arrowhead Pharmaceuticals, Inc. Company Details Table 93. Arrowhead Pharmaceuticals, Inc. Business Overview Table 94. Arrowhead Pharmaceuticals, Inc. Product Table 95. Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 96. Arrowhead Pharmaceuticals, Inc. Recent Development Table 97. Carolus Therapeutics, Inc. Company Details Table 98. Carolus Therapeutics, Inc. Business Overview Table 99. Carolus Therapeutics, Inc. Product Table 100. Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 101. Carolus Therapeutics, Inc. Recent Development Table 102. Cevec Pharmaceuticals GmbH Company Details Table 103. Cevec Pharmaceuticals GmbH Business Overview Table 104. Cevec Pharmaceuticals GmbH Product Table 105. Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 106. Cevec Pharmaceuticals GmbH Recent Development Table 107. Dicerna Pharmaceuticals, Inc. Company Details Table 108. Dicerna Pharmaceuticals, Inc. Business Overview Table 109. Dicerna Pharmaceuticals, Inc. Product Table 110. Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 111. Dicerna Pharmaceuticals, Inc. Recent Development Table 112. Digna Biotech, S.L. Business Overview Table 113. Digna Biotech, S.L. Product Table 114. Digna Biotech, S.L. Company Details Table 115. Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 116. Digna Biotech, S.L. Recent Development Table 117. Editas Medicine, Inc. Company Details Table 118. Editas Medicine, Inc. Business Overview Table 119. Editas Medicine, Inc. Product Table 120. Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 121. Editas Medicine, Inc. Recent Development Table 122. Grifols, S.A. Company Details Table 123. Grifols, S.A. Business Overview Table 124. Grifols, S.A. Product Table 125. Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 126. Grifols, S.A. Recent Development Table 127. Inhibrx Company Details Table 128. Inhibrx Business Overview Table 129. Inhibrx Product Table 130. Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 131. Inhibrx Recent Development Table 132. Intellia Therapeutics, Inc. Company Details Table 133. Intellia Therapeutics, Inc. Business Overview Table 134. Intellia Therapeutics, Inc. Product Table 135. Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 136. Intellia Therapeutics, Inc. Recent Development Table 137. International Stem Cell Corporation Company Details Table 138. International Stem Cell Corporation Business Overview Table 139. International Stem Cell Corporation Product Table 140. International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 141. International Stem Cell Corporation Recent Development Table 142. Ionis Pharmaceuticals, Inc. Company Details Table 143. Ionis Pharmaceuticals, Inc. Business Overview Table 144. Ionis Pharmaceuticals, Inc. Product Table 145. Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 146. Ionis Pharmaceuticals, Inc. Recent Development Table 147. Kamada Ltd. Company Details Table 148. Kamada Ltd. Business Overview Table 149. Kamada Ltd. Product Table 150. Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 151. Kamada Ltd. Recent Development Table 152. Polyphor Ltd. Company Details Table 153. Polyphor Ltd. Business Overview Table 154. Polyphor Ltd. Product Table 155. Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 156. Polyphor Ltd. Recent Development Table 157. ProMetic Life Sciences Inc. Company Details Table 158. ProMetic Life Sciences Inc. Business Overview Table 159. ProMetic Life Sciences Inc. Product Table 160. ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 161. ProMetic Life Sciences Inc. Recent Development Table 162. rEVO Biologics, Inc. Company Details Table 163. rEVO Biologics, Inc. Business Overview Table 164. rEVO Biologics, Inc. Product Table 165. rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 166. rEVO Biologics, Inc. Recent Development Table 167. Sangamo BioSciences, Inc. Company Details Table 168. Sangamo BioSciences, Inc. Business Overview Table 169. Sangamo BioSciences, Inc. Product Table 170. Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$) Table 171. Sangamo BioSciences, Inc. Recent Development Table 172. Research Programs/Design for This Report Table 173. Key Data Information from Secondary Sources Table 174. Key Data Information from Primary Sources List of Figures Figure 1. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Type: 2020 VS 2026 Figure 2. CT-2009 Features Figure 3. POL-6014 Features Figure 4. ARO-AAT Features Figure 5. ALNAAT-02 Features Figure 6. Others Features Figure 7. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026 Figure 8. Clinic Case Studies Figure 9. Hospital Case Studies Figure 10. Others Case Studies Figure 11. Alpha- Antitrypsin Deficiency Treatment Report Years Considered Figure 12. Global Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2015-2026 (US$ Million) Figure 13. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions: 2020 VS 2026 Figure 14. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2021-2026) Figure 15. Porter's Five Forces Analysis Figure 16. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Players in 2019 Figure 17. Global Top Alpha- Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2019 Figure 18. The Top 10 and 5 Players Market Share by Alpha- Antitrypsin Deficiency Treatment Revenue in 2019 Figure 19. North America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 20. Europe Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 21. China Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Japan Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 23. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 24. India Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 25. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 26. Adverum Biotechnologies, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 27. Adverum Biotechnologies, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 28. Alnylam Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 29. Alnylam Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 30. Applied Genetic Technologies Corporation Total Revenue (US$ Million): 2019 Compared with 2018 Figure 31. Applied Genetic Technologies Corporation Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 32. Arrowhead Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 33. Arrowhead Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 34. Carolus Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 35. Carolus Therapeutics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 36. Cevec Pharmaceuticals GmbH Total Revenue (US$ Million): 2019 Compared with 2018 Figure 37. Cevec Pharmaceuticals GmbH Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 38. Dicerna Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 39. Dicerna Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 40. Digna Biotech, S.L. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 41. Digna Biotech, S.L. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 42. Editas Medicine, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 43. Editas Medicine, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 44. Grifols, S.A. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 45. Grifols, S.A. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 46. Inhibrx Total Revenue (US$ Million): 2019 Compared with 2018 Figure 47. Inhibrx Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 48. Intellia Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 49. Intellia Therapeutics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 50. International Stem Cell Corporation Total Revenue (US$ Million): 2019 Compared with 2018 Figure 51. International Stem Cell Corporation Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 52. Ionis Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 53. Ionis Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 54. Kamada Ltd. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 55. Kamada Ltd. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 56. Polyphor Ltd. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 57. Polyphor Ltd. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 58. ProMetic Life Sciences Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 59. ProMetic Life Sciences Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 60. rEVO Biologics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 61. rEVO Biologics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 62. Sangamo BioSciences, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 63. Sangamo BioSciences, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) Figure 64. Bottom-up and Top-down Approaches for This Report Figure 65. Data Triangulation Figure 66. Key Executives Interviewed

Adverum Biotechnologies, Inc. Alnylam Pharmaceuticals, Inc. Applied Genetic Technologies Corporation Arrowhead Pharmaceuticals, Inc. Carolus Therapeutics, Inc. Cevec Pharmaceuticals GmbH Dicerna Pharmaceuticals, Inc. Digna Biotech, S.L. Editas Medicine, Inc. Grifols, S.A. Inhibrx Intellia Therapeutics, Inc. International Stem Cell Corporation Ionis Pharmaceuticals, Inc. Kamada Ltd. Polyphor Ltd. ProMetic Life Sciences Inc. rEVO Biologics, Inc. Sangamo BioSciences, Inc.